|Mr. Duncan Joseph Peyton||CEO & Exec. Director||141.59k||N/A||1970|
|Dr. Alexander James Stevenson||Chief Scientific Officer & Exec. Director||141.59k||N/A||1972|
|Fay Weston||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Adrian Murray||Gen. Counsel (Interim)||N/A||N/A||N/A|
|Mr. Glenn Dourado||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Richard Avison||Group Fin. Director||N/A||N/A||N/A|
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
4D pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.